Lord, Abbett & Co’s MoonLake Immunotherapeutics MLTX Stock Holding History

Lord, Abbett & Co’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-86,487	Closed	-$4.34M	–	569
2024 Q1	$4.34M	Sell	86,487 -72,832	-46%	-$3.95M	0.01%	489
2023 Q4	$9.62M	Sell	159,319 -16,718	-9%	-$862K	0.03%	394
2023 Q3	$10M	Sell	176,037 -18,666	-10%	-$1.03M	0.04%	386
2023 Q2	$9.93M	Buy	+194,703	New	+$5.24M	0.03%	418

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Lord, Abbett & Co's MLTX Position: Q2 2024 in Review

Lord, Abbett & Co sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2024, closing a stake of 86,487 shares — an estimated $4.34M sold.

Lord, Abbett & Co first reported a position in MLTX in Q2 2023 and held it in 4 quarters. The position peaked at $10M in Q3 2023. 111 funds tracked by Wall St. Rank hold MLTX as of Q2 2024.

Lord, Abbett & Co reported no remaining MoonLake Immunotherapeutics position as of Q2 2024 after selling out during the quarter.
Lord, Abbett & Co sold 86,487 MoonLake Immunotherapeutics shares in Q2 2024, an estimated $4.34M.
Lord, Abbett & Co first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 4 quarters.
Lord, Abbett & Co's MoonLake Immunotherapeutics position peaked at $10M in Q3 2023.
111 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2024.

Based on Lord, Abbett & Co's 13F filing for Q2 2024, filed 14 Aug 2024.